Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care

By Johnny Rice Benzinga

DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzingas All-Access.

GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The companys vision is to create a future where diabetes management is automatic and inconspicuous, empowering people to live boldly and unapologetically.

Learn more here:

https://www.youtube.com/watch?v=xjn-_aLseTc&feature=youtu.be

Featured photo by Towfiqu barbhuiya on Unsplash .

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga . Read further disclosures here.

Copyright 2025 JCN Newswire . All rights reserved.

You May Also Be Interested In

• Critical One Energy Provides Update on Kenora Property and Claim Against American Atomics Inc.
• Dolphin Entertainment Reports Second Quarter 2026 Results
• Yatra Online, Inc. Announces Results for the Three Months Ended June 30, 2026